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Chronic inflammatory diseases such as periodontitis have been associated with increased risk for various medical conditions
including diabetes and cardiovascular disease. Endotoxin (lipopolysaccharide, LPS), derived from gram-negative periodonto-
pathogens, can induce the local accumulation of mononuclear cells in the inflammatory lesion, increasing proinflammatory
cytokines and matrix metalloproteinases (MMPs). This ultimately results in the destruction of periodontal connective tissues
including alveolar bone. Curcumin is the principal dyestuff in the popular Indian spice turmeric and has significant regulatory
effects on inflammatory mediators but is characterized by poor solubility and low bioactivity. Recently, we developed a series of
chemically modified curcumins (CMCs) with increased solubility and zinc-binding activity, while retaining, or further enhancing,
their therapeutic effects. In the current study, we demonstrate that a novel CMC (CMC 2.5: 4-methoxycarbonyl curcumin) has
significant inhibitory effects, better than the parent compound curcumin, on proinflammatory cytokines and MMPs in in vitro,
in cell culture, and in an animal model of periodontal inflammation. The therapeutic potential of CMC 2.5 and its congeners may
help to prevent tissue damage during various chronic inflammatory diseases including periodontitis and may reduce the risks of
systemic diseases associated with this local disorder.
1. Introduction
Periodontal disease is one of the most common chronic
inflammatory diseases encountered in humans. During the
pathogenesis of this condition, anaerobic gram-negative
periodontal-associated pathogens (e.g., P. gingivalis, T.
forsythia) and the lipopolysaccharide (LPS, endotoxin) in
their cell walls stimulate the innate and adaptive immune
responses in periodontal tissues [1]. Inflammatory cells such
as neutrophils and monocytes/macrophages are recruited to
the lesion site and generate elevated levels of cytokines and
other proinflammatorymediators such as the prostaglandins.
The resulting periodontal inflammation upregulates matrix
metalloproteinase (MMP) expression and, the activity of the
latter, contributes to the destruction and loss of periodontal
connective tissues including bone [2].
Curcumin [1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-
heptadiene-3,5-dione] is a component of the popular Indian
spice turmeric and has been recommended for numerous
medical applications [3]. Extensive investigations have led
to the conclusion that it is a highly pleiotropic molecule
with significant beneficial effects on inflammatory and other
diseases including cancers such as multiple myeloma [3–5].
This natural product has long been used as an herbal anti-
inflammatory treatment to relieve pain and inflammation
in the skin and muscles and, for a variety of pulmonary,
gastrointestinal and liver diseases, as well as a remedy for
nonhealing wounds. These therapeutic effects have been
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studied in both in vitro and in vivo model systems [6–8].
Despite these many beneficial effects, curcumin has major
limitations including poor solubility, a lack of systemic
bioavailability, and rapid metabolic disposition [9]. Thus,
extremely high oral doses of the compound are needed
and, even then, it results in only very low levels in the
systemic circulation of both animals and humans. This
has severely limited its clinical application [10]. Recently,
our laboratory has developed a series of novel chemically
modified curcumins with a carbonyl substituent at the
C-4 position [11, 12]. Such analogues have an additional
electron-withdrawing group which enhances their anti-
inflammatory therapeutic effects. One such compound
(CMC 2.5) contains a methoxycarbonyl group at C4, shows
an improved solubility, better serum albumin-binding
activity, and greater acidity, and enhanced zinc-binding
characteristics. This modification has been found to enhance
the MMP-inhibitory properties of this novel compound
versus curcumin [11, 12].
In the current report, we investigate the effect of this
novel substance, 4-methoxycarbonylcurcumin (CMC 2.5),
on proinflammatory cytokines and MMPs in an in vivo
diabetes-enhanced periodontal inflammation rat model and
in a relevant cell culture model. Rats with experimental
diabetes mellitus manifest increased gingival inflammation
and periodontal tissue destruction including alveolar bone
loss [13–16]. This animal model of STZ-induced diabetes as
an enhancer of periodontal disease is well established in
our laboratory [14, 15] and has been described by others
as well [16]. It was used in preclinical studies during the
development of Periostat, the only host modulation and
MMP inhibitory therapy for periodontitis approved by the
FDA. This unique animal model, different from traditional
rat models of experimental periodontitis using ligatures or
oral pathogen infection, will allow us to study the possible
association between this local inflammatory disease and
relevant systemic conditions. We have previously demon-
strated that the diabetic condition increases the levels of
cytokines and MMPs locally in the gingival tissues as well
as systemically in plasma [14, 15]. In addition, levels of
MMP-8 in skin and both local and systemic bone loss were
increased in this animal model [17]. Therefore, this will
allow us to study not only the periodontal disease, but also
the systemic factors associated with this local inflammatory
condition.
In addition, a periodontal disease-relevant cell culture
system involving human mononuclear cells challenged with
LPS (derived from the periodontal pathogen, P. gingivalis)
was also used to evaluate the effect of CMC2.5 on the induced
excessive levels of proinflammatory MMPs and cytokines.
Nuclear factor-kappaB (NF-𝜅B) is a transcription factor
involved in the cell signaling transduction pathway associated
with inflammation and plays a key role in regulating the cellu-
lar immune response to stimuli such as stress, cytokines, and
bacterial or viral antigens [18]. Dysregulation of NF-𝜅B has
been linked to cancer and inflammatory diseases [18]. There-
fore, the effect of CMC 2.5 on the activation/phosphorylation
of NF-𝜅B was evaluated as well.
2. Materials and Methods
2.1. Chemical Reagents. All chemical reagents, LPS from P.
gingivalis and curcumin, were purchased fromSigma-Aldrich
Co. (St. Louis, MO). All cell culture reagents were purchased
from Gibco/Invitrogen Corp. (Carlsbad, CA). CMC 2.5 was
synthesized, purified (99.5% pure), and provided by Chem
Master Intl. Inc., Stony Brook, NY.
2.2. InVitroMMP InhibitionAssay (IC
50
). Human chromato-
graphically pure MMP-9 was purchased from Calbiochem,
EMD Biosciences, Inc. (La Jolla, CA), MMP-13 was pur-
chased from R&D Systems, Inc. (Minneapolis, MN), and the
synthetic octapeptide MMP substrate (DNP-Pro-Gln-Gly-
Ile-Ala-Gly-Gln-dArg) was purchased from Bachem (King
of Prussia, PA). Curcumin and CMC 2.5 (1–500 𝜇M) were
incubated in 1mM CaCl
2
, 0.2M NaCl, and 50mM Tris/HCl
buffer (pH = 7.6) with MMP-9 (gelatinase B) or MMP-
13 (collagenase-3) at 37∘C for 4 hours as described by us
previously [11]. The reaction mixture was quenched with
1,10-phenanthroline (a zinc chelator that binds this cation
in the MMP molecule), and the tripeptide degradation frag-
ments of the synthetic octapeptide substrate, after incubation
(37∘C, lmMCa2+) with each MMP, were measured by high-
performance liquid chromatography (HPLC) using a reverse-
phase C18 column (4.6 × 75mm, 3.5 𝜇Mmacroporous spher-
ical support).The eluate was monitored at 375 nm to quantify
the DNP-labeled peptides. The IC
50
for each compound was
calculated from the plot of the percentage of inhibition of
enzyme activity versus the concentration of inhibitor [19, 20].
2.3. Cell Culture Assay. Human peripheral blood mononu-
clear cells (PBMC) were isolated and purified from Leuko-
cyte Concentrate (Long Island Blood Bank, Melville, NY)
by density gradient centrifugation and adherence using a
method described by us previously [21]. PBMC cells were
then cultured for 18 hours in serum-free macrophage media
(Invitrogen Corp, Carlsbad, CA) at 37∘C (95% air, 5% CO
2
)
with either LPS derived from P. gingivalis (50 ng/mL) or
vehicle alone. Curcumin or CMC 2.5 was added at final con-
centrations of 2 or 5 𝜇M. Conditioned media were analyzed
for the cytokines and proinflammatory mediators, TNF-𝛼,
IL-1𝛽, IL-6, MCP-1, and PGE
2
by ELISA (see below) and for
MMP-9 by ELISA and by gelatin zymography (see below) as
described previously [21, 22].
2.4. Gelatin Zymography. The gelatin zymography system
and SDS-PAGE gels, containing polyacrylamide copolymer-
ized with gelatin at a final concentration of 1mg/mL, were
purchased from Invitrogen Corp. (Carlsbad, CA). After elec-
trophoresis (120V), the gels were washed with 2.5% Triton
X-100, incubated at 37∘C overnight in calcium assay buffer
(40mM Tris/HCl, 200mMNaCl, 10mM CaCl
2
, and pH 7.5),
and then stained with Coomassie Brilliant Blue R-250. As
described by us earlier [19], clear zones of lysis against a blue
background indicate gelatinolytic activity and were scanned
densitometrically to assess gelatinase activity. MMP-2 and
MMP-9 standards were purchased from R&D Systems, Inc.
(Minneapolis, MN).
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2.5. ELISA Assay. ELISA kits for TNF-𝛼, IL-1𝛽, IL-6, MCP-
1, PGE
2
, and MMP-9 were purchased from R&D Systems,
Inc. (Minneapolis, MN). Fifty or 100 𝜇L of the reconstituted
standards or samples of conditioned medium was plated
into wells coated with anti-human primary antibody and
then incubated with 50𝜇L of a biotinylated detection anti-
body reagent, at room temperature for two hours. After
incubation, the plates were washed three times and 100 𝜇L
of streptavidin-HRP solution was added to each well and
incubated for 30 minutes at room temperature. Following
three further washes, 3,3󸀠, 5,5󸀠󸀠-tetramethylbenzidine (TMB)
substrate solution (100 𝜇L) was added to each well and the
plate was allowed to develop at room temperature in the dark.
After 30 minutes, 100 𝜇L of stop solution was added and the
absorbance of the samples was measured at 450 nm [20].
2.6. NF𝜅B Activation Assay. The phosphorylation of NF𝜅B
was measured by means of a Cellular Activation of Signaling
ELISA (CASE) kit (SABiosciences, Frederick, MD). PBMC
cells were cultured in serum-free macrophage media (37∘C,
95% air, 5% CO
2
) for 18 hours with LPS (P. gingivalis,
50 ng/mL) or vehicle alone, and CMC 2.5 was added at a
final concentration of 5𝜇M. Following the incubation, the
cells were treated with 4% cell fixing buffer. The wells were
washed, quenched, and blocked for 1 hour at 22∘C and then
incubated with anti-human primary antibodies specific to
either phosphorylated or total NF𝜅B protein, for 1 hour at
room temperature. After incubation, the plate was washed
three times with a buffered surfactant (phosphate buffered
saline containing Tween 20), HRP-conjugated secondary
antibody solution was added to each well, and the plate was
incubated for 60 minutes at room temperature. Following
three further washes, a color developing solution was added
to each well and the plate was allowed to develop at room
temperature in the dark. After 10 minutes, stop solution was
added and the absorbance of each sample was measured at
450 nm [23].
2.7. Animal Studies. All of the experimental procedures
involving animals were approved by Stony Brook University’s
Institutional Animal Care and Use Committee (IACUC).
Twelve male Sprague-Dawley rats (275–300 g body weight;
viral antibody free; Charles River Labs) were injected i.v.
with streptozotocin (STZ), 70mg/kg, to induce diabetes and
diabetes-enhanced periodontal disease in diabetic rats [14,
15]. Diabetic status was confirmed weekly using a glucose
test strip which showed >2% glucose in urine within 24–
48 h after STZ injection. Nondiabetic control rats (NDC,
𝑛 = 6) were injected i.v. with the vehicle (citric buffer)
alone. One to two days after STZ injection, when glucosuria
had been established, six of the STZ-diabetic rats were daily
administered for 3 weeks, by oral gavage, a 1mL suspension
of CMC 2.5 (100mg/kg body weight suspended in 2%
carboxymethylcellulose) or 1mL of vehicle alone (𝑛 = 6 rats).
At the end of the treatment period, the rats were sacrificed
by exsanguination, blood samples were collected, and gingiva
were dissected and pooled by group, because insufficient
gingival tissue is available for individual analysis. Blood
glucose levels were analyzed by a blood glucose monitoring
system (Johnson and Johnson, Milpitas, CA). Blood samples
and gingival tissues were stored at −80∘C until analyzed for
MMPs and cytokines, by gelatin zymography and ELISA,
respectively.
2.8. Gingival Extracts. The pooled gingival tissues from
each group of rats were weighed, minced (all procedures at
4∘C), and extracted with Tris-NaCl-CaCl
2
buffer (pH 7.6;
100mg wet weight gingival tissue/5mL buffer) containing
5M urea [14, 15]. After centrifugation, the supernatant was
dialyzed exhaustively against the Tris/NaCl/CaCl
2
buffer,
and the extract was partially purified by precipitation with
ammonium sulfate, added to 60% saturation. Aliquots of
each gingival extract were measured for MMP-2 and MMP-
9 by gelatin zymography and were scanned densitometrically
to quantify gelatinase activity; IL-1𝛽 was measured using a
commercial ELISA kit (R&D systems, Minneapolis, MN).
2.9. Western Blot Analysis. Samples were treated with
Laemmli buffer (pH 7.0) containing 5mM dithiothreitol and
heated for 5 minutes at 100∘C. High- and low-range pre-
stained sodium dodecyl sulfate- (SDS-) polyacrylamide gel
electrophoresis standard proteins were used as molecular
weight markers. The samples were electrophoresed on 7.5%
SDS-polyacrylamide gels and then electrophoretically trans-
ferred to nitrocellulosemembranes.Western blot analysiswas
carried out as described by us previously [20].
Specific immunoreactivity was visualized as dark bands
against a clear background, and themembranes were scanned
with an imaging densitometer (Bio-Rad Model GS-700, Bio-
Rad, Hercules, CA) using a program (Analyst, Bio-Rad,
Hercules, CA) that corrects for background absorption. The
densitometric units were measured in the linear range of
immunoreactivity forMMP-13; purified humanMMP-13 was
used as a positive control.
2.10. Statistical Analysis. Cytokine and MMP differences in
cell culture between groups were analyzed by Student’s 𝑡-
test, with 𝑃 ≤ 0.05 taken as statistically significant. In the
rat animal studies, when comparing two groups (normal
versus untreated diabetic; untreated diabetic versus diabetic
treated with CMC 2.5), a student’s 𝑡-test was used as well; 𝑃
values ≤ 0.05 were considered statistically significant.
3. Results
3.1. In Vitro MMP Inhibition Studies. Each human chro-
matographically pure MMP was incubated in vitro with
the collagenase-specific synthetic octapeptide substrate as
previously described [20]. For each compound tested as an
MMP inhibitor (phenanthroline, curcumin, or CMC 2.5),
the concentrations, ranging from 1, 5, 20, to 100 𝜇M, that
was required to inhibit 50% of the proteolytic activity of
the MMP (IC
50
, see Table 1) was determined from a plot of
the extent (%) of inhibition versus the concentration of the
inhibitor. 1,10-Phenanthroline, a zinc binding agent [11], was
used to quench the in vitroMMP assays. Curcumin was used
as a positive control. CMC 2.5 was found to inhibit both
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Table 1: Potency of CMC 2.5 as an MMP inhibitor.
Test compounds MMP-9 MMP-13
IC50 (𝜇M) Maximum inhibition (%) IC50 (𝜇M) Maximum inhibition (%)
1,10-Phenanthroline 9 100 4 100
Curcumin 29 58 110 53
CMC 2.5 16 72 15 69
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Figure 1: Inhibition of TNF-𝛼 levels by curcumin and CMC 2.5
in PBMC cells. PBMC cells (5 × 105 cells/well) were cultured in
serum-free media (37∘C, 95% air, 5% CO
2
) for 18 hours with LPS (P.
gingivalis, 50 ng/mL) or vehicle alone. Curcumin or CMC 2.5 was
added at final concentrations of 2 or 5 𝜇M. Conditioned medium
was analysed for TNF-𝛼 by ELISA. Each value represents the mean
of 3 cultures ± the standard error of the mean (S.E.M.). ∗𝑃 < 0.05
represents the significance of all groups of curcumin and CMC 2.5
compared to LPS alone; ∗∗𝑃 < 0.05 represents the significance
between LPS + 5𝜇M curcumin and LPS + 5 𝜇MCMC 2.5.
MMP-9 and MMP-13 activities in a dose-response fashion in
vitro (data not shown) and was two-seven times more potent
(based on IC
50
values) as an MMP inhibitor than its parent
compound, curcumin (Table 1).
3.2. Cell Culture Studies. As noted in Figure 1, in our cell
culture studies, control wells were incubated with monocytes
in serum-free conditioned media (SFCM) (37∘C, 95% air, 5%
CO
2
) for 18 hourswith LPS (P. gingivalis, 50 ng/mL) or vehicle
alone. In the absence of CMC 2.5 and LPS, about 200 pg/mL
of TNF-𝛼 was secreted by the monocytes which increased
to 1470 pg/mL when LPS was added to the culture. TNF-𝛼
levels were reduced by 13% and 46% with either 2 or 5 𝜇M
curcumin, respectively; however, only the latter value was
statistically significant (𝑃 < 0.05). In contrast, when CMC 2.5
was added to the culture of the LPS-stimulated monocytes,
in final concentrations of 2 or 5𝜇M, a greater effect was
seen at both concentrations; the extracellular TNF-𝛼 levels
were decreased by 45% (𝑃 < 0.05) and 79% (𝑃 < 0.05),
respectively. In addition, 5𝜇M CMC 2.5 was found to be
72% more potent as an inhibitor of TNF-𝛼 secretion than
5 𝜇M curcumin (𝑃 < 0.05). Similarly, monocytes secreted
185 pg/mL of IL-1𝛽 when LPS was added to the culture in
contrast to the <25 pg/mL by control cells (Figure 2). IL-1𝛽
levels were reduced by 57% and 83% with 2 and 5 𝜇M
curcumin, respectively (𝑃 < 0.05). When these cells were
incubated in the presence of CMC 2.5 at concentrations of
2 and 5 𝜇M, both concentrations of CMC 2.5 decreased IL-
1𝛽 levels by more than 90%, essentially back to the values
seen in cells that were not treated with LPS (Figure 2). All
four treatments were statistically significant compared to
LPS alone. In fact, 2 𝜇M CMC 2.5 was 75% more effective
than 2𝜇M curcumin (𝑃 < 0.05) as an inhibitor of IL-1𝛽
secretion, although the 5 𝜇MCMC 2.5 which appeared to
be 50% more effective than 5 𝜇M curcumin did not differ
significantly from the effect of 5𝜇M curcumin (𝑃 > 0.05).
A similar pattern of change was observed for PGE
2
levels
(Figure 3); CMC 2.5 at concentrations of 2 and 5𝜇M reduced
extracellular PGE
2
levels by 23% (𝑃 > 0.05) and 51% (𝑃 <
0.05), respectively, compared to LPS alone. In addition, the
extracellular levels of MCP-1, IL-6, and MMP-9 (the latter
a major MMP secreted by monocytes) in the SFCM from
these monocyte cultures, in the presence or absence of 5𝜇M
CMC 2.5, were analyzed by ELISA and gelatin zymography,
respectively. Similar to the results observed for IL-1𝛽, the
extracellular levels of these bioactive proteins were reduced
by more than 90%, essentially down to untreated cell values
(Figures 4 and 5) by 5𝜇MCMC 2.5, and these effects were all
statistically significant (𝑃 < 0.05). In contrast, curcumin at
5 𝜇M concentration did not have a significant effect onMCP-
1, IL-6 (data not shown), or MMP-9 levels (Figure 5).
To begin to explore the underlyingmechanisms of action,
the levels of phosphorylation of NF𝜅B (p65/S536) in the
presence of CMC 2.5 were analyzed by calculating the
percent phosphorylation relative to total NF𝜅B protein levels
(Figure 6). In these cultures, control wells were incubated
with monocytes in serum-free conditioned media (SFCM;
37∘C, 95% air, 5% CO
2
) for 18 hours with LPS (P. gingivalis,
50 ng/mL) or vehicle alone. The phosphorylation of NF𝜅B
was increased 3-fold in the presence of LPS (Figure 6). When
CMC 2.5 was added to the culture of the LPS-stimulated
monocytes in a final concentration of 5𝜇M, the phosphory-
lation of NF-𝜅B was decreased by 35.4% (𝑃 ≤ 0.05).
Thus, in these cell culture studies, LPS from gram-
negative bacteria, P. gingivalis, increased the secretion
of TNF-𝛼, PGE
2
, IL-1𝛽, IL-6, MCP-1, and MMP-9 and
increased the phosphorylation (activation) of NF-𝜅B in
human mononuclear cells. All of these effects were largely
normalized by CMC 2.5. Therefore, the in vivo therapeutic
potential of this chemically modified curcumin (CMC 2.5)
was further evaluated in the diabetes/periodontal inflamma-
tion rat model as described below.
3.3. In Vivo Studies. The diabetic condition was induced in
the rats by STZ as described above. CMC 2.5 (100mg/kg) was
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Figure 2: Inhibition of IL-1𝛽 levels by curcumin and CMC 2.5
in PBMC cells. PBMC cells (5 × 105 cells/well) were cultured in
serum-free media (37∘C, 95% air, 5% CO
2
) for 18 hours with LPS
(P. gingivalis, 50 ng/mL) or vehicle alone. Curcumin or CMC 2.5 was
added at final concentrations of 2 or 5 𝜇M.Conditionedmediumwas
analysed for IL-1𝛽 by ELISA. Each value represents the mean of 3
cultures ± S.E.M. ∗𝑃 < 0.05 represents the significance of all groups
of curcumin and CMC 2.5 compared to LPS alone; ∗∗𝑃 < 0.05
represents the significance betweenLPS+ 2 𝜇Mcurcumin andLPS +
2𝜇MCMC 2.5.
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Figure 3: Inhibition of PGE
2
levels by CMC 2.5 in PBMC cells.
PBMC cells (5 × 105 cells/well) were cultured in serum-free media
(37∘C, 95% air, 5% CO
2
) for 18 hours with LPS (P. gingivalis,
50 ng/mL) or vehicle alone. CMC 2.5 was added at final concen-
trations of 2 or 5𝜇M. Conditioned medium was analysed for PGE
2
by ELISA. Each value represents the mean of 3 cultures ± S.E.M.
∗
𝑃 < 0.05.
administered orally for 3 weeks beginning after the diabetic
condition was established. As expected, we found that the
diabetic condition markedly increased the activity of MMP-
9 in both plasma and gingiva (Figures 7 and 8). In addition,
MMP-13, which in the rats is analogous toMMP-1 in humans
[24], was also increased in the plasma of the diabetic rats
(Figure 7), whereas MMP-13 was not detected in the pooled
gingival tissues. In the plasma, CMC2.5 reduced the excessive
MMP-9 and MMP-13 levels to near normal levels. However,
the effects of both diabetes and CMC 2.5 treatment on plasma
MMP-2were not statistically significant, although the pattern
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Figure 4: Inhibition of MCP-1, IL-6, and MMP-9 levels by CMC
2.5 in PBMC cells. PBMC cells (5 × 105 cells/well) were cultured in
serum-free media (37∘C, 95% air, 5% CO
2
) for 18 hours with LPS
(P. gingivalis, 50 ng/mL) or vehicle alone. CMC 2.5 was added at a
final concentration of 5𝜇M. Conditioned medium was analysed for
MCP-1 or IL-6 orMMP-9 by ELISA. Each value represents themean
of 3 cultures ± S.E.M. ∗𝑃 < 0.05.
of change for this 72 kDa gelatinase paralleled the changes
seen for the other MMPs (Figure 7). It should be noted
that the elevated blood glucose (Figure 9) and HbA1c (data
not shown) levels in the diabetic rats were not affected by
CMC 2.5 treatment. In the gingiva, the dominant gelatinase
in this periodontal tissue in the nondiabetic control rats
is MMP-2, present both as the 72 kDa proform and as the
lower molecular weight activated form. Inducing diabetes
and severe hyperglycemia results in the induction of MMP-
9 (92 kDa gelatinase) in the gingival tissues, but this effect is
“normalized” by CMC 2.5 treatment in spite of there being
no effect on the severity of the hyperglycemia (Figure 9). Note
that the levels/activity ofMMP-2 in the gingiva is not affected
either by diabetes or by treatment with CMC 2.5. Moreover,
the diabetic rats exhibited approximately 200% higher IL-1𝛽
levels in the gingiva compared to the normal rats, but the
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Vehicle LPS alone
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curcumin
LPS + 2𝜇m
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Figure 5: Inhibition of MMP-9 levels by CMC 2.5 in PBMC cells. PBMC cells (5 × 105 cells/well) were cultured in serum-free media (37∘C,
95% air, 5% CO
2
) for 18 hours with LPS (P. gingivalis, 50 ng/mL) or vehicle alone. CMC 2.5 was added at a final concentration of 5𝜇M.
Conditioned medium was analyzed for MMP-9 by gelatin zymography.
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Figure 6: Inhibition of NF𝜅B phosphorylation by CMC 2.5 in
PBMC cells. PBMC cells (5 × 104 cells/well) were cultured in serum-
free media (37∘C, 95% air, 5% CO
2
) for 18 hours with LPS (P.
gingivalis, 50 ng/mL) or vehicle alone. CMC 2.5 was added at a
final concentration of 5𝜇M. Following the incubation, cells were
fixed and phosphorylation of NF𝜅B was analyzed by CASE cellular
activation of signaling ELISA kit. ∗𝑃 ≤ 0.05.
oral administration of CMC 2.5 reduced this level in pooled
gingival tissue, by 26% (Figure 8).
4. Discussion
Curcumin is considered a safemolecule and has been used for
thousands of years as a food additive inAsia [25]. Structurally,
studies have shown that curcumin contains a 𝛽-diketone
zinc binding site [25] similar to that in the tetracycline-
based MMP inhibitors [26]. In the current study, CMC
2.5 demonstrated greater therapeutic activity, compared to
curcumin, based on its improved inhibitory activity against
MMPs and proinflammatory cytokines in in vitro and in
cell culture; it also showed efficacy in an animal model of
diabetes-enhanced periodontal inflammation (see below). To
verify that the inhibition of the MMPs (MMP-9 and MMP-
13) and proinflammatory mediators (TNF-𝛼, IL-1𝛽, MCP-1,
IL-6, and PGE
2
) by CMC 2.5 was not the result of cell tox-
icity, the Cell Proliferation Assay, using a novel tetrazolium
compound to determine cell cytotoxicity (MTS assay), was
also performed (data not shown). These data demonstrated
that CMC 2.5 at doses used in our assay is not toxic to the
human mononuclear cells in culture. In additional studies
(not shown), no adverse effects were observed in the diabetic
rats orally administered doses as high as 500mg/kg body
weight once per day, over a 3-week protocol (much higher
than the oral dose used in the current study, 100mg/kg)
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Figure 7:The effect of diabetes and orally administered CMC 2.5 on
plasma MMPs. Male Sprague-Dawley rats (𝑛 = 6) were injected i.v.
with streptozotocin (STZ) 70mg/kg to induce diabetes, as described
by us previously. STZ-diabetic rats were daily administered by oral
gavage CMC2.5 (100mg/kg) for 3 weeks. At the end of the treatment
protocol, rats were sacrificed by exsanguination; blood samples
were collected and analyzed for MMP-9 by gelatin zymography and
MMP-13 by Western blot, and were scanned densitometrically to
quantify the levels of MMP-9 and MMP-13. ∗𝑃 < 0.05.
[17]. In fact, oral administration of 100mg/kg CMC 2.5 to
the diabetic rats attenuated the complications caused by the
severely hyperglycemic condition such as bleeding under the
nails, severely inflamed sclera, and impaired wound healing,
without any detectable effect on blood glucose or HbA1c
levels.This indicates that CMC 2.5 can reduce the destructive
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Figure 8: The effect of diabetes and orally administered CMC 2.5 on gingival MMPs (-2, -9) and IL-1𝛽. Gingival tissue from diabetic rats
treated with vehicle or CMC 2.5 was obtained and pooled by group as described in Section 2, since insufficient gingival tissue is usually
available for individual analysis. Gingival tissues were then extracted and aliquots of each gingival extract were measured for MMP-2 and
MMP-9 by gelatin zymography and were scanned densitometrically to quantify gelatinase activity, and IL-1𝛽 was measured by ELISA. NDC:
nondiabetic control; UD: untreated diabetic.
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Figure 9: The effect of diabetes and orally administered CMC
2.5 on blood glucose levels. Male Sprague-Dawley rats (𝑛 = 6)
were injected i.v. with streptozotocin (STZ) 70mg/kg to induce
diabetes, as described by us previously. STZ-diabetic rats were
daily administered by oral gavage CMC 2.5 (100mg/kg) for 3
weeks. At the end of the treatment protocol, rats were sacrificed by
exsanguination; blood samples were then collected and analyzed for
blood glucose levels by the blood glucose monitoring system. NDC:
nondiabetic control; UD: untreated diabetic.
effects of the inflammatory mediators (cytokines andMMPs)
during local (periodontal disease) and systemic (diabetes)
conditions without exhibiting toxicity.
To begin to understand the underlying mechanisms of
the inhibitory effects of CMC 2.5 on inflammatory mediators
secreted by humanmononuclear cells, the phosphorylation of
NF-𝜅B was evaluated. Since NF-𝜅B controls transcription of
many genes involved in inflammation, it is found chronically
activated in many inflammatory diseases such as arthritis
[27]. The upregulation of proinflammatory cytokines and
MMPs may be mediated through the NF-𝜅B as well as other
intracellular signaling transduction pathways including P38
MAP kinase [28]. In the current study, we have shown that
LPS stimulation of human monocytes increased, by 3-fold,
the phosphorylation of NF𝜅B and that CMC 2.5 can sig-
nificantly reduce this excessive NF𝜅B activation. Therefore,
the increased production of these inflammatory mediators
may be regulated, at least partially, through the NF-𝜅B cell
signaling transduction pathways, and CMC 2.5 treatment can
attenuate this effect.
Diabetes is recognized as an important risk factor for
chronic periodontitis based on human clinical trials [29].The
current view is that the hyper- (or prolonged-) inflammatory
response during diabetes is mainly caused by the long-term
exposure of various proteins to elevated glucose levels. This
results in the formation of advanced glycation end-products
(AGEs) which promote the secretion of proinflammatory
mediators (e.g., TNF-𝛼, IL-1𝛽, and IL-6) and alters the
innate immune response [2, 14], as well as increasing the
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production and activity of tissue and bone-destructiveMMPs
[15, 30]. These abnormalities progress to periodontal tissue
destruction that is initiated by bacterial factors such as LPS.
On the other hand, periodontitis can be more than just
a localized chronic inflammation. This oral disease may
also have profound effects on the systemic health of the
diabetic patient. During the pathogenesis of periodontal
disease, the host immunoinflammatory response to plaque
bacteria produces destructive cytokines such as TNF-𝛼, IL-
1𝛽, and MMPs [2]. Initially, this response is protective in
nature and designed to control the bacterial infection; this
can be observed clinically as gingival inflammation with no
alveolar bone loss. However, when the above inflammatory
process is not well controlled, it results in excessive levels
of the inflammatory mediators and MMPs, as seen in dia-
betes. These inflammatory mediators can eventually enter
into the circulation, stimulating a systemic inflammatory
responsewhich then increases the risk for developing diabetic
complications including an increased risk for cardiovascular
disease [2]. In this regard, the interrelationships between
diabetes and periodontal disease may represent a “two-hit”
model in which diabetes predisposes the patient to oral tissue
destruction, and the oral infection exacerbates the abnormal
glucose metabolism and its complications in the patient with
diabetes [30]. Thus, effective management of both local and
systemic inflammation is critical to attenuate these severe
complications.
Studies have shown that greater gingival inflammation
and periodontal tissue destruction including alveolar bone
loss can be observed in diabetic rat models [13–16]. Specif-
ically, in our in vivo rat model, we have previously demon-
strated [14, 15] that inducing diabetes with streptozotocin
(STZ) increases, both systemically (plasma) and locally (gin-
giva), the levels of cytokines and MMPs which are associated
with the collagen and bone destruction that characterize
periodontal disease. Alveolar bone loss has been found to
be increased in this animal model of diabetes as well [14–
16]. Importantly, a number of studies have not found signifi-
cant differences in periodontal pathogens in the subgingival
biofilm in comparing the nondiabetic controls and diabetic
humans or rats, indicating that host-response differences
between these two groups are largely responsible for the
excessively severe periodontal disease in poorly controlled
diabetic patients [31]. In the current study, cytokines and
MMPs levels were increased, and oral administration of CMC
2.5 to the diabetic rats significantly reduced the MMP-9
and MMP-13 levels in plasma and decreased both MMP-
9 and IL-1𝛽 levels in rat gingival tissue, with no detectable
effect on blood glucose orHbA1c levels. However, statistically
significant elevated periodontal bone loss in the diabetics
was not observed. But, preliminary data in a previous study
indicated that CMC 2.5 administration to diabetic rats did
significantly reduce alveolar bone loss (𝑃 < 0.05) [17]. The
inconsistency regarding diabetes-induced alveolar bone loss,
between the earlier and current studies, may be due to the
duration of each study. Changes in inflammatory biomarkers
in gingiva presumably occur at an earlier stage while alveolar
bone loss takes more time; therefore the latter occurs at a
later stage of the disease. In addition, any differences in the
age of the rats in the different studies may also play a role
in the alveolar bone response to the diabetic condition and
drug treatment. Longer term studies, to examine the effects
of CMC 2.5 and related congeners on alveolar bone loss in
the diabetic rats, are currently underway. In addition, we are
also working on a rat model of experimental periodontitis,
that is, LPS injection into the gingiva, and have preliminary
data showing thatCMC2.5 reduces bothMMPs in the gingiva
and alveolar bone loss in defleshed jaws in this model. These
will be discussed in future reports. Of specific interest, the
current study indicates that CMC 2.5 reduces excessive levels
of inflammatory cytokines and MMPs in the gingiva and
plasma of the diabetic rats at the 3-week time period. This
suggests that before the clinical signs of progressive periodon-
titis are observed, CMC 2.5 can prevent the progression to
clinically evident periodontitis (characterized by bone loss),
by reducing these inflammatory mediators both locally and
systemically at an early stage of the disease. This could also
reduce the risk of developing diabetic complications over
longer periods of hyperglycemia.
In addition, the in vitro MMP inhibition assays were
carried out with MMP-9 (92 kDa gelatinase) and MMP-13
(collagenase-3), both known to be associated with periodon-
tal disease and other conditions of connective tissue loss [19,
32]. Our study indicates that CMC 2.5 can inhibit bothMMP-
9 and MMP-13 activities directly and that CMC 2.5 is more
potent as an MMP inhibitor than the parent compound, cur-
cumin. Moreover, the cell culture studies indicate that CMC
2.5 can significantly reduce the MMP-9 and cytokine levels
(TNF-𝛼, IL-1𝛽, MCP-1, IL-6, and PGE
2
) produced by chronic
inflammatory cells, in response to the microbial endotoxin,
LPS. In addition to monocytes, human polymorphonuclear
leukocytes (neutrophils, PMNs) also form an essential part
of the innate immune system and play a critical role in
acute inflammation. Our studies now underway have shown
significant impairment of PMN function in diabetic rats,
specifically, reduced PMN chemotaxis and abnormal PMN
accumulation in peritoneal exudates from these animals.
Moreover, oral administration of a CMC reduced the severity
of these abnormalities. These findings will be detailed in
future reports [33].
The findings presented in this paper support the hypoth-
esis that a chemically modified curcumin (CMC 2.5) is a
pleiotropic compound, having both intracellular and extra-
cellular effects which, collectively, ameliorate local and sys-
temic inflammation and prevent hyperglycemia-associated
tissue destruction. Safety and toxicity studies on CMC 2.5
on two animal species, for example, rats and dogs, will be
needed to enable proof-of-concept preliminary clinical trials
in patients with periodontal disease. Our ultimate goal is to
complete additional animal studies and advance to human
clinical trials. Future studies using this or related novel
CMCs could also test the safety and efficacy of these com-
pounds on animal models of other inflammatory diseases
such as rheumatoid arthritis and diabetes-induced impaired
wound healing. In conclusion, CMC 2.5, a methoxycar-
bonyl curcumin, demonstrated therapeutic potential in treat-
ing inflammatory and connective tissue-destructive diseases
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such as periodontal disease and may also reduce the risks of
other complications of diabetes.
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